BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd. (6733) - Total Assets
Latest total assets as of December 2025: NT$815.38 Million TWD
Based on the latest financial reports, BioGend Therapeutics Co., Ltd. (6733) holds total assets worth NT$815.38 Million TWD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioGend Therapeutics Co., Ltd. - Total Assets Trend (2021–2025)
This chart illustrates how BioGend Therapeutics Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioGend Therapeutics Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
BioGend Therapeutics Co., Ltd.'s total assets of NT$815.38 Million consist of 78.1% current assets and 22.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 26.7% |
| Accounts Receivable | NT$58.96 Million | 7.2% |
| Inventory | NT$20.52 Million | 2.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BioGend Therapeutics Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioGend Therapeutics Co., Ltd.'s current assets represent 78.1% of total assets in 2025, an increase from 71.7% in 2021.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2025, up from 13.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
BioGend Therapeutics Co., Ltd. Competitors by Total Assets
Key competitors of BioGend Therapeutics Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BioGend Therapeutics Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioGend Therapeutics Co., Ltd. generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioGend Therapeutics Co., Ltd. is currently not profitable relative to its asset base.
BioGend Therapeutics Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.60 | 21.60 | 25.33 |
| Quick Ratio | 17.03 | 21.12 | 24.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$600.27 Million | NT$ 684.47 Million | NT$ 696.30 Million |
BioGend Therapeutics Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between BioGend Therapeutics Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.12 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | NT$815.38 Million |
| Market Capitalization | $9.69K USD |
Valuation Analysis
Below Book Valuation: The market values BioGend Therapeutics Co., Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioGend Therapeutics Co., Ltd.'s assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioGend Therapeutics Co., Ltd. (2021–2025)
The table below shows the annual total assets of BioGend Therapeutics Co., Ltd. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$815.38 Million | -10.66% |
| 2024-12-31 | NT$912.70 Million | -13.12% |
| 2023-12-31 | NT$1.05 Billion | +27.82% |
| 2022-12-31 | NT$821.82 Million | -19.73% |
| 2021-12-31 | NT$1.02 Billion | -- |